Researchers identify off switch for alcoholism
Researchers from Monash University and the Florey Institute have made a potential breakthrough in the ability to treat alcohol addiction with a simple drug.
Professor Mark Febbraio wins the 2020 GSK Award for Research Excellence
Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has become the 40th winner of the prestigious GSK Award for Research Excellence.
Monash University scientist wins prestigious Eureka Prize for ground-breaking research into treating metabolic disease
Professor Mark Febbraio from the Monash Institute of Pharmaceutical Sciences (MIPS) has been awarded the 2020 Australian Museum Eureka Prize, the nation’s top science award.
Leading Australian metabolic disease researcher wins Society of Endocrinology International Medal
Prominent metabolic disease researcher Professor Mark Febbraio, from the Monash Institute of Pharmaceutical Sciences (MIPS), has been awarded the 2021 International Medal from the UK’s Society of Endocrinology.
Breakthrough discovery paves the way for preventing sugar-induced liver disease
A team of international researchers including Monash University academics has discovered that, contrary to previous belief, fructose causes liver toxicity by changing the barrier function of the intestine.
New international collaboration showcases drug development potential
New research from Monash Institute of Pharmaceutical Sciences (MIPS), in collaboration with the Max Planck Institute, Mayo Clinic, University of Auckland, University of Essex and University of Tokyo, has uncovered new structures of protein
MIPS and Thermo Fisher announce ‘GPCR Cryo-EM and Drug Design’ collaboration
A new collaboration between MIPS researcher Professor Patrick Sexton’s team and the leading biological cryo-EM biotechnology product development company, Thermo Fisher Scientific, will bring cryo-electron microscopy of G protein-coupled
Weaning ourselves off opioids: Monash researchers use nanotechnology for pain relief
Researchers at the Monash Institute of Pharmaceutical Sciences (MIPS) and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology (CBNS) have created a nanoparticle that could improve the properties of painkillers by delivering